🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Multiple-Dose Study on the Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diaprel® MR) in Healthy Participants under Fed Conditions.

    The George Institute

    No medical condicion.

    phase 1 other active

    1 trial

  2. N-acetylcysteine

    Ultragenyx UK Limited

    Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  3. NBI-77860

    NEUROCRINE BIOSCIENCES INC

    Congenital Adrenal Hyperplasia

    phase 1 small molecule terminated

    1 trial

  4. NNC 0172-0000-2021

    Novo Nordisk A/S

    Congenital Bleeding Disorder

    phase 1 small molecule completed

    1 trial

  5. NatrunixTM

    XBiotech Germany GmbH

    Pharmacokinetics

    phase 1 mab active

    1 trial

  6. NeoTISLEGA - A phase Ib trial evaluating the safety and activity of neoadjuvant combination of tislelizumab plus FLOT for resectable esophagogastric adenocarcinoma

    The George Institute

    resectable esophagogastric adenocarcinoma

    phase 1 other active

    1 trial

  7. NeuroRegen scaffold with BMMCs or MSCs transplantation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Spinal Cord Injury

    phase 1 mab active

    1 trial

  8. OMP-54F28, Nab-Paclitaxel and Gemcitabine

    Mereo BioPharma Group plc

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  9. OPB-51602

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma

    phase 1 small molecule terminated

    1 trial

  10. OPC1

    Lineage Cell Therapeutics

    Spinal Cord Injury Cervical

    phase 1 mab active

    1 trial

  11. Obecabtagene autoleucel (obe-cel)

    Autolus GmbH

    Progressive Multiple Sclerosis

    phase 1 mab active

    1 trial

  12. Obecabtagene autoleucel (obe-cel)

    Autolus GmbH

    Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial

  13. Odronextamab

    Regeneron UK Limited

    B-cell Non-Hodgkins Lymphoma (B-NHL)

    phase 1 small molecule active

    1 trial

  14. Odronextamab multiple dose levels

    Regeneron UK Limited

    Non-Hodgkin Lymphoma

    phase 1 small molecule completed

    1 trial

  15. Ologen Collagen Matrix

    AEON Biopharma

    Congenital Glaucoma

    phase 1 other active

    1 trial

  16. Olutasidenib Investigational Agent Administration

    RIGEL PHARMACEUTICALS INC

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  17. Omega 3 fatty acid

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Male Infertility Due to Hypospermatogenesis

    phase 1 small molecule active

    1 trial

  18. Open label, single-center, two-part pharmacokinetic study: Part I: Relative bioavailability study to compare the pharmacokinetics of BP1.4979 after administration of single oral doses of BP1.4979 as sustained release formulation and actual immediate release formulation, under fasting and fed conditions, in healthy subjects. Part II: Pharmacokinetics of BP1.4979 after a 14-day dosing period with b.i.d. administration of BP1.4979 as sustained release formulation in healthy subjects.

    Bioprojet Pharma

    Binge eating disorder

    phase 1 other active

    1 trial

  19. Optical PD-L1 imaging using Quantitative Fluorescence Endoscopy in locally advanced esophageal cancer using durvalumab-680LT: a phase I multicenter feasibility and safety study

    Disc Medicine

    Esophageal cancer

    phase 1 other active

    1 trial

  20. Oral Fosmanogepix

    Basilea Pharmaceutica

    Healthy

    phase 1 small molecule completed

    1 trial

  21. Oxcarbazepine (brand name vs generic drugs)

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 1 small molecule completed

    1 trial

  22. Oxidized regenerated cellulose(ORC)

    Hospital Authority, Hong Kong

    Thyroidectomy

    phase 1 small molecule completed

    1 trial

  23. Oxytocine and migraine

    Disc Medicine

    This is a study in healthy volunteers. We will study the trigeminovascular system, which is relevant in the pathophysiology of migraine.

    phase 1 other active

    1 trial

  24. PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib

    Chongqing Precision Biotech Co., Ltd

    Non-small Cell Lung Cancer

    phase 1 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources